Gossamer Bio is developing therapeutics in immunology, inflammation and oncology. Gossamer Bio’s main strategy is in-licensing of drugs. Through the use of small molecule libraries, Gossamer discovers, develops and acquires drugs that have therapeutic value for diseases with high unmet need. Gossamer tailors in vitro assays to test their drug targets and uses a variety of biochemical techniques and reporter assays. Promising hits are then further investigated in tumor models before entering clinical trials. Gossamer has an ongoing Phase I clinical trial for Primary CNS Lymphoma with multiple preclinical programs in development.